TW363063B - Arylalkyl diazinone - Google Patents

Arylalkyl diazinone

Info

Publication number
TW363063B
TW363063B TW085109458A TW85109458A TW363063B TW 363063 B TW363063 B TW 363063B TW 085109458 A TW085109458 A TW 085109458A TW 85109458 A TW85109458 A TW 85109458A TW 363063 B TW363063 B TW 363063B
Authority
TW
Taiwan
Prior art keywords
arylalkyl
carbon atoms
diazinone
formula
physiologically acceptable
Prior art date
Application number
TW085109458A
Other languages
English (en)
Inventor
Rochus Jonas
Michael Wolf
Norbert Beier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of TW363063B publication Critical patent/TW363063B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Polymerization Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
TW085109458A 1995-09-14 1996-08-05 Arylalkyl diazinone TW363063B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19533975A DE19533975A1 (de) 1995-09-14 1995-09-14 Arylalkyl-diazinone

Publications (1)

Publication Number Publication Date
TW363063B true TW363063B (en) 1999-07-01

Family

ID=7772083

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085109458A TW363063B (en) 1995-09-14 1996-08-05 Arylalkyl diazinone

Country Status (24)

Country Link
US (1) US5859008A (zh)
EP (1) EP0763534B1 (zh)
JP (1) JP4149532B2 (zh)
KR (1) KR970015578A (zh)
CN (1) CN1110495C (zh)
AT (1) ATE233258T1 (zh)
AU (1) AU716113B2 (zh)
BR (1) BR9603736A (zh)
CA (1) CA2185397C (zh)
CZ (1) CZ286567B6 (zh)
DE (2) DE19533975A1 (zh)
DK (1) DK0763534T3 (zh)
ES (1) ES2192213T3 (zh)
HU (1) HUP9602511A3 (zh)
MX (1) MX9604020A (zh)
NO (1) NO309679B1 (zh)
PL (1) PL185961B1 (zh)
PT (1) PT763534E (zh)
RU (1) RU2167159C2 (zh)
SI (1) SI0763534T1 (zh)
SK (1) SK281474B6 (zh)
TW (1) TW363063B (zh)
UA (1) UA48946C2 (zh)
ZA (1) ZA967766B (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
EE04312B1 (et) * 1997-12-15 2004-06-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihüdrobensofuraanid, nende kasutamine ravimite valmistamiseks ning neid sisaldavad ravimid
CA2323771A1 (en) * 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
WO2001030766A1 (en) 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pde 4 inhibitors
KR20020043238A (ko) 1999-10-25 2002-06-08 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 Pde4 억제제로서의 테트라히드로티오피란프탈라지논유도체
CA2411351A1 (en) 2000-06-05 2001-12-13 Altana Pharma Ag Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
KR20040012720A (ko) * 2001-02-12 2004-02-11 메르크 파텐트 게엠베하 심근 질환에서 제 4형 포스포디에스테라제 저해제의 용도
IL156812A0 (en) 2001-02-15 2004-02-08 Altana Pharma Ag Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
IL157908A0 (en) 2001-04-25 2004-03-28 Altana Pharma Ag Phthalazinone derivatives and pharmaceutical compositions containing the same
IL157870A0 (en) 2001-04-25 2004-03-28 Altana Pharma Ag Piperazino derivatives and pharmaceutical compositions containing the same
PL366792A1 (en) * 2001-07-18 2005-02-07 Merck Patent Gmbh 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies
DE10150517A1 (de) * 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
EP1463509A1 (en) * 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
DE10227269A1 (de) * 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
AU2003260376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
EP1556369A1 (en) * 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
ATE390419T1 (de) 2004-02-04 2008-04-15 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-o - derivate als pde4-inhibitoren
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005055354A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005055355A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3429996A4 (en) 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. SMALL MOLECULES DIRECTED AGAINST CEREBLON TO IMPROVE THE FUNCTION OF T EFFECTOR LYMPHOCYTES
KR20210032430A (ko) 2018-07-11 2021-03-24 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 세레블론-기반 메커니즘에 대한 이량체 면역-조절 화합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788476A (fr) * 1971-09-08 1973-03-06 Sandoz Sa Nouveaux derives de la pyridazinone, leur preparation et leur application comme medicaments
DE3505609A1 (de) * 1985-02-19 1986-08-21 Merck Patent Gmbh, 6100 Darmstadt Benzimidazolyl-pyridazinone
AU614965B2 (en) * 1987-06-06 1991-09-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Thiadiazinones
DE3734083A1 (de) * 1987-10-08 1989-04-20 Heumann Pharma Gmbh & Co Benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
DE4134893A1 (de) * 1991-10-23 1993-04-29 Merck Patent Gmbh Thiadiazinone
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
DE4330915C1 (de) * 1993-09-11 1994-09-08 Steinel Bernhard Werkzeugmasch Palettenwechsler für Werkzeugmaschinen
DE19500558A1 (de) * 1995-01-11 1996-07-18 Merck Patent Gmbh 3-Alkoxycarbonyl-thiadiazinone
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
DE19514568A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone

Also Published As

Publication number Publication date
SK281474B6 (sk) 2001-04-09
DK0763534T3 (da) 2003-06-10
DE19533975A1 (de) 1997-03-20
CN1110495C (zh) 2003-06-04
CZ263096A3 (cs) 1998-03-18
PL185961B1 (pl) 2003-09-30
EP0763534B1 (de) 2003-02-26
UA48946C2 (uk) 2002-09-16
KR970015578A (ko) 1997-04-28
NO963852D0 (no) 1996-09-13
AU6551796A (en) 1997-03-20
JPH09124611A (ja) 1997-05-13
CA2185397A1 (en) 1997-03-15
BR9603736A (pt) 1998-05-26
HUP9602511A2 (en) 1997-03-28
ES2192213T3 (es) 2003-10-01
ATE233258T1 (de) 2003-03-15
KR100435301B1 (zh) 2004-09-07
MX9604020A (es) 1997-03-29
PL316070A1 (en) 1997-03-17
US5859008A (en) 1999-01-12
ZA967766B (en) 1997-03-26
EP0763534A1 (de) 1997-03-19
JP4149532B2 (ja) 2008-09-10
SI0763534T1 (en) 2003-10-31
AU716113B2 (en) 2000-02-17
RU2167159C2 (ru) 2001-05-20
NO963852L (no) 1997-03-17
SK110096A3 (en) 1997-08-06
NO309679B1 (no) 2001-03-12
DE59610164D1 (de) 2003-04-03
CZ286567B6 (cs) 2000-05-17
CA2185397C (en) 2010-01-05
HU9602511D0 (en) 1996-11-28
CN1157287A (zh) 1997-08-20
HUP9602511A3 (en) 1998-04-28
PT763534E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
TW363063B (en) Arylalkyl diazinone
ES8202546A1 (es) Metodo de producir derivados de tiazolidina
IL107292A0 (en) Substituted benzylaminoquinuclidines
MX9606709A (es) Inhibidores de metaloproteasas de matriz.
ES8400730A1 (es) Un procedimiento para preparar derivados de tetralina
UA43391C2 (uk) Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
ES2012527A6 (es) Procedimiento de obtencion de benzo(b) piranos y piranopiridinas.
MY131501A (en) Process for the prepration of clavulanic acid
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
MY108891A (en) Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor
ES8302671A1 (es) "procedimiento de preparacion de nuevos derivados 3,4-dihidro-5h-2,3-benzodiazepinos y de sus sales de adicion acidas farmaceuticamente aceptables".
HUP9900851A2 (hu) Benzotiofénszármazékok felhasználása véredény simaizom sejtek migrálásának inhibiálására alkalmas gyógyszerkészítmények előállítására
BG102759A (en) Therapeutical form for diabetes
IE872588L (en) Compounds
ES8500209A1 (es) Procedimiento para la preparacion de derivados de carbaciclina
ES8301915A1 (es) Procedimiento para preparar derivados de 2-oxoazetidina .
ES8606337A1 (es) Un procedimiento para preparar nuevas benzamidas con actividada antagonista de 5-ht.
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
BG103207A (en) Esters of the arylcycloalkanecarboxylic acids, their application, pharmaceutical compositions and their preparation
ES8407066A1 (es) Derivados de 6 -metilprednisolona.
UA42731C2 (uk) Арилалкілтіадіазинони, спосіб їх отримання, фармацевтична композиція, спосіб її отримання, спосіб лікування
YU140391A (sh) 6-supstituisani-heksahidrobenz (cd)-indoli
TW334428B (en) Novel benzodiazepine derivatives
IE800620L (en) Tetrahydrothiophenes
ES8400396A1 (es) "procedimiento de preparacion de derivados de amino-2-tetrahidro-1,2,3,4-naftaleno".